1st International Conference on Polyploid Giant Cancer Cells: Biology and Clinical Applications

LIVEPolyploid
1st International Conference on Polyploid Giant Cancer Cells: Biology and Clinical Applications Banner

Add to Calendar 1st International Conference on Polyploid Giant Cancer Cells: Biology and Clinical Applications 2/16/2024 8:00:00 AM 2/17/2024 4:00:00 PM America/Chicago For More Details: https://mdanderson.cloud-cme.com/Polyploid2024 Description: We cordially invite Scientists, Oncologists, Post-Doctoral Fellows, and Graduate Students engaged in cancer research to join us for the inaugural International Conference on Polyploid Giant Cancer Cells.Over the past century, pathologists have observed distinctively large mononucleated or multinucleated giant cancer cells, termed polyploid giant cancer cells (PGCCs). These cells, characterized by multiple copies of... MD Anderson - Duncan Building false MM/DD/YYYY


Date & Location
Friday, February 16, 2024, 8:00 AM - Saturday, February 17, 2024, 4:00 PM, MD Anderson - Duncan Building, Houston, TX

Target Audience
Specialties - Medical Oncology, Pathology, Pathology - Anatomic, Radiation Oncology
Professions - Other, Physician (MD or DO), Student or Trainee

Credits
AMA PRA Category 1 Credits™ (11.25 hours), Non-Physician Attendance (11.25 hours)

Overview

We cordially invite Scientists, Oncologists, Post-Doctoral Fellows, and Graduate Students engaged in cancer research to join us for the inaugural International Conference on Polyploid Giant Cancer Cells.

Over the past century, pathologists have observed distinctively large mononucleated or multinucleated giant cancer cells, termed polyploid giant cancer cells (PGCCs). These cells, characterized by multiple copies of the genome, significantly contribute to nuclear atypia—a crucial diagnostic criterion in cancer grading and malignancy assessment.
Detected in approximately 37-50% of human cancers, polyploid genomes represent one of the most prevalent genetic alterations in cancer. PGCCs, prevalent in high-grade malignant tumors across various organs—such as the breast, ovary, uterus, pancreas, colon, lung, brain, and in leukemia, lymphoma, and sarcoma—are now a subject of extensive study.

Previously considered senescent and nonviable due to their inability to undergo mitosis, recent years have witnessed a transformative shift in understanding PGCCs. These cells represent a stress-responsive mechanism, demonstrating mitosis-independent growth resembling early embryogenesis. This characteristic impacts immortality, malignant transformation, invasion, metastasis, dormancy, and resistance. Their embryonic properties have revitalized century-old embryonic cancer theories, reshaping our comprehension of cancer on organismal and tissue-development levels

The emerging study of PGCCs holds significant promise for understanding cancer and improving patient outcomes by enhancing therapeutic efficacy, reducing resistance, and enabling early detection. The dedicated special issue on PGCCs in underscores the paramount importance of this field. www.sciencedirect.com

 

Conference Chair, Jinsong Liu, MD,PhD and Conference Co-Chair, Donna Hansel, MD, PhD 

 

This international conference aims to gather cancer scientists, pathologists, and clinicians in this burgeoning field to discuss current insights and disseminate ideas. Together, we aspire to translate findings into clinical practice and save lives from cancer. This is a crucial step in ensuring that scientific research is effectively applied to the diagnosis, treatment, and care of cancer patients.


Objectives
At the conclusion of this activity, learners will be able to:

  1. Describe how PGCCs relate to both embryogenesis and cancer progression.
  2. Evaluate the potential of PGCCs in early cancer detection, diagnosis, and therapy resistance.
  3. Investigate and learn brand-new concepts about this emerging field of cancer biology.

Registration
1st International Conference on Polyploid Giant Cancer Cells: Biology and Clinical Applications - February 16, 2024. The conference will begin at 8:30 AM, and will adjourn at 3:35PM, Saturday, February 17.  Location: Dan L. Duncan Building, 1155 Pressler St. Floor 8, Houston, TX 77030, Conference Center Rooms 1-8
  •  Registration fee includes tuition for this in-person Live Activity.
  •  The deadline for advanced registration is January 16, 2024.
Registration Category Fee: 
 

 

We accept the following forms of payment:

  • Credit Cards (MasterCard, VISA, and American Express)
  • Check (Payable to The University of Texas MD Anderson Cancer Center; through U.S. banks only)

Mail checks to:
Continuing Professional Education – Unit 1781
The University of Texas MD Anderson Cancer Center
P.O. Box 301407
Houston, Texas 77230-1407

When registering online a receipt (confirmation letter) will be automatically emailed to the e-mail address you list on the registration form. 
Telephone registrations are not accepted.

Special Assistance:
Contact Continuing Professional Education / Activity Management at 713-792-2223 or 866-849-5866. You may also email CPE at [email protected].

Refund/Cancellation Policy: 
The registration fee, minus a $25 administration-handling fee, is refundable if a written request is received on or before February 2, 2024. No refunds will be granted after these dates. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. 
 
Continuing Professional Education (CPE), reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary.  Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form. In case of activity cancellation, the liability of the CPE is limited to the registration fee. CPE will refund the full registration fee. 
 
CPE reserves the right to limit the number of participants in an activity and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. 

 

Ground Transportation:
Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU).  The following ground transportations are available to and from the airports to the Medical Center.

     • Uber and Lyft
     • Taxicabs: Yellow Cab 713-236-1111; Fiesta Cab 713-225-2666.
     • Super Shuttle: For more information, call toll free at 800-258-3826, or on-line at www.supershuttle.com.

Evaluation:
A course evaluation tool will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.  The survey link will be provided during the review course.

 

For additional information or Special Assistance, contact CPE at 713-792-2223 or toll free at 866-849-5866 or via e-mail: [email protected].

 


Accreditation

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation: 
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 11.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Additional Information

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.